This Sith Lord proved that dying was just a minor setback! Join us as we count down the most iconic and memorable moments ...

Hell hath no fury like a person wronged! Join us as we count down some of the most jaw-dropping real-life revenge stories ...

Unless you’re an El Pasoan or a sojourner who has visited the downtown museum that richly captures the city’s complex history, you probably wouldn’t know that it’s been a hell of a century for Texas’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Top women executives share how being underestimated shaped ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

Top women executives share how being underestimated shaped their leadership — and how to turn doubt into lasting success. Being underestimated is a near-universal experience, particularly for women ...

Fiona Wilkes does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

Alphabet (GOOG), Google’s Gemini Robotics with vision-language-action models and AutoRT system for controlling robot swarms positions it as a leading physical AI play trading at 27.1x forward P/E.

Company leaders have long claimed that people are their greatest asset. Yet many still design work as if employees were just one of many operational inputs, leaving their greatest assets feeling ...

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a particular interest in mental health, gender-affirming care, and LGBTQ+ patient ...

The Houston Texans are making a strong statement in free agency. The Texans are coming for the AFC South division and more in 2026. The team is quietly doing so with offensive line additions. Earlier ...

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is ...